{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:59:10Z","timestamp":1792785550828,"version":"4.5.0"},"reference-count":49,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ponsored by Pfizer Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1080\/21645515.2023.2251825","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:45:36Z","timestamp":1694133936000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Real-world impact and effectiveness of MenACWY-TT"],"prefix":"10.1080","volume":"19","author":[{"given":"Rodolfo","family":"Villena","sequence":"first","affiliation":[{"name":"Universidad de Chile","place":["Santiago, Chile"]},{"name":"Hospital de ni\u00f1os Dr. Exequiel Gonz\u00e1lez Cort\u00e9s","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Kriz","sequence":"additional","affiliation":[{"name":"National Institute of Public Health","place":["Prague, Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myint","family":"Tin Tin Htar","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Burman","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7954-11-17"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.063"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.060"},{"key":"e_1_3_4_5_1","unstructured":"WHO. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. [accessed 2022 Jan 27]. https:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules."},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60842-4"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1557520"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab791"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.07.004"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.051"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.48"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.010"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30301-8"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz336"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800245"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.007"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.079"},{"key":"e_1_3_4_18_1","unstructured":"Nimenrix (meningococcal group A C W-135 and Y conjugate vaccine). Summary of Product Characteristics Pfizer Manufacturing Belgium N.V. Belgium; 2017."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.1990"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.075"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00335-7"},{"key":"#cr-split#-e_1_3_4_22_1.1","unstructured":"Public Health England. Vaccine coverage estimates for the meningococcal ACWY (MenACWY) adolescent vaccination programme in schools across England in 2018\/19"},{"key":"#cr-split#-e_1_3_4_22_1.2","unstructured":"and for the GP-based catch-up programme to end of August 2019. [accessed 2022 Jan 27]. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/953825\/hpr0220_menACWY-vc.pdf."},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2020.44.10"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2019.042"},{"key":"e_1_3_4_25_1","unstructured":"National center for immunisation research and surveillance Australia. Annual immunisation coverage report; 2020 [accessed 2022 Jul 27]. https:\/\/www.ncirs.org.au\/sites\/default\/files\/2022-07\/NCIRS%20Annual%20Immunisation%20Coverage%20Report%202020.pdf."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2019.43.66"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.050"},{"key":"e_1_3_4_28_1","unstructured":"Australian Bureau of Statistics. [accessed 2022 Mar 2]. https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/dec-2020."},{"key":"e_1_3_4_29_1","unstructured":"United Nations Development Progamme. [accessed 2022 Mar 2]. http:\/\/hdr.undp.org\/en\/indicators\/44206."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1855952"},{"key":"e_1_3_4_31_1","unstructured":"Vaccine schedules in all countries in the EU\/EEA. [accessed 2022 Feb 9]. https:\/\/vaccine-schedule.ecdc.europa.eu\/."},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2307.170236"},{"key":"e_1_3_4_33_1","unstructured":"National Health Service MenACWY Vaccine. [accessed 2022 Jun 22]. https:\/\/www.nhs.uk\/conditions\/vaccinations\/men-acwy-vaccine\/."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.20473"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-116"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001123"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.064"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1248009"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1058457"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.02.030"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111675"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.6.688"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1086\/527401"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61612-8"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.06.080"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix596"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S28410"},{"key":"e_1_3_4_48_1","unstructured":"Informe Regional SIREVA 2017. Argentina Informaci\u00f3n sobre la vigilancia de las neumon\u00edas y meningitis bacterianas. SIREVA II. OPS. 2019 Neisseria meningitidis. http:\/\/antimicrobianos.com.ar\/ATB\/wp-content\/uploads\/2021\/01\/Meningo-2019.pdf."},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/13607863.2012.692766"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2023.2251825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:56:40Z","timestamp":1770818200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2023.2251825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1080\/21645515.2023.2251825"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2023.2251825","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2251825"}}